687 related articles for article (PubMed ID: 28137296)
1. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
2. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
3. Antimony susceptible
Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
[TBL] [Abstract][Full Text] [Related]
4. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Singh N; Chatterjee M; Sundar S
Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Kumar D; Kulshrestha A; Singh R; Salotra P
Antimicrob Agents Chemother; 2009 Feb; 53(2):835-8. PubMed ID: 19015344
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.
Prajapati VK; Sharma S; Rai M; Ostyn B; Salotra P; Vanaerschot M; Dujardin JC; Sundar S
Am J Trop Med Hyg; 2013 Oct; 89(4):750-4. PubMed ID: 23980130
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
Pandey K; Ravidas V; Siddiqui NA; Sinha SK; Verma RB; Singh TP; Dhariwal AC; Das Gupta RK; Das P
Am J Trop Med Hyg; 2016 Nov; 95(5):1100-1105. PubMed ID: 27645786
[TBL] [Abstract][Full Text] [Related]
9. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
10. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
11. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
12. Iron superoxide dismutase contributes to miltefosine resistance in Leishmania donovani.
Veronica J; Chandrasekaran S; Dayakar A; Devender M; Prajapati VK; Sundar S; Maurya R
FEBS J; 2019 Sep; 286(17):3488-3503. PubMed ID: 31087522
[TBL] [Abstract][Full Text] [Related]
13. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
Ostyn B; Hasker E; Dorlo TP; Rijal S; Sundar S; Dujardin JC; Boelaert M
PLoS One; 2014; 9(6):e100220. PubMed ID: 24941345
[TBL] [Abstract][Full Text] [Related]
14. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
Mishra J; Madhubala R; Singh S
Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
[TBL] [Abstract][Full Text] [Related]
15. Leishmania resistance to miltefosine associated with genetic marker.
Cojean S; Houzé S; Haouchine D; Huteau F; Lariven S; Hubert V; Michard F; Bories C; Pratlong F; Le Bras J; Loiseau PM; Matheron S
Emerg Infect Dis; 2012 Apr; 18(4):704-6. PubMed ID: 22469394
[No Abstract] [Full Text] [Related]
16. Evaluating drug resistance in visceral leishmaniasis: the challenges.
Hendrickx S; Guerin PJ; Caljon G; Croft SL; Maes L
Parasitology; 2018 Apr; 145(4):453-463. PubMed ID: 27866478
[TBL] [Abstract][Full Text] [Related]
17. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.
Carnielli JBT; Crouch K; Forrester S; Silva VC; Carvalho SFG; Damasceno JD; Brown E; Dickens NJ; Costa DL; Costa CHN; Dietze R; Jeffares DC; Mottram JC
EBioMedicine; 2018 Oct; 36():83-91. PubMed ID: 30268832
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance in Indian visceral leishmaniasis.
Sundar S
Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
[TBL] [Abstract][Full Text] [Related]
19. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
Thakur CP; Dedet JP; Narain S; Pratlong F
Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558
[TBL] [Abstract][Full Text] [Related]
20. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Mishra J; Singh S
Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
